SUMMARY We report the case of a 40-year-old female with acute onset of systemic lupus erythematosus, followed rapidly by the development of fatal pneumonitis and disseminated intravascular coagulation. The likely relationship between these events and the therapeutic options are discussed.
Acute pneumonitis is a rare complication of systemic lupus erythematosus (SLE). It may be a presenting feature of the disease and carries a poor prognosis.1 Minor coagulation abnormalities are common in SLE, but severe disseminated intravascular coagulation (DIC) has rarely been reported.
We report a patient who died of acute lupus pneumonitis complicated by DIC. The likely relationship between these two events and the therapeutic options for such a problem are discussed.
Case history
A 40-year-old Indian woman presented in 1982 with a six-week history of symmetrical polyarthritis involving proximal interphalangeal joints, wrists, elbows, knees, and toes. She had a 3-year history of Raynaud's phenomenon but no history of alopecia, sun sensitivity, oral ulceration, serositis, renal, or central nervous system disease. Treatment included a variety of non-steroidal anti-inflammatory drugs.
Accepted for publication 10 Acute interstitial pneumonitis was diagnosed in our patient by bronchoalveolar lavage and transbronchial biopsy. Infection and other causes of pneumonitis were excluded by the history, histology, persistently negative sputum cultures, cytol-ogy, and failure to respond to cessation of all anti-inflammatory drugs or addition of corticosteroids. Acute interstitial pneumonitis is a rare complication of SLE, the largest series reporting 12 patients, six of whom died.3 Pneumonitis occurs more frequently in MCTD, but is usually responsive to corticosteroids. More severe cases, unresponsive to steroids, sometimes have pulmonary vasculitis, which was not present in our case. 4 Disseminated intravascular coagulation was diagnosed in our patient on the basis of thrombocytopenia, prolonged prothrombin time, partial thromboplastin time and thrombin time, low fibrinogen, and the presence of fibrin degradation products. In addition our patient had widespread thrombosis at necropsy. Severe DIC is rare in SLE5 6 and has not been reported in MCTD. There has been recent interest in the role of the lupus anticoagulant in thrombosis in SLE. 7 We did not specifically look for this in our patient's short illness, and it is possible that it played a part in the widespread thrombosis found post mortem. It is interesting that the renal histology and immunofluorescence were similar to those in the series of SLE patients with lupus anticoagulant described by Kant et al. 8 DIC may be a primary cause of lung disease manifest as the adult respiratory distress syndrome.9 In our patient coagulation tests were normal at the onset of her illness, suggesting that DIC was a secondary event. DIC may also cause deterioration of lung function in severely ill patients by means of thrombosis in small pulmonary vessels, and it is likely that this was a major factor in our patient.
Effective therapy of acute pneumonitis in connective tissue diseases is not established. In a series of patients with interstitial pneumonitis survival depended on the initial degree of dyspnoea, age, cellular histology, and early response to steroid.t0 The presence of a connective tissue disease did not affect the outcome. There are also occasional reports of benefit from azathioprine, cyclophosphamide, and penicillamine." 12 Our clinical impression was that cyclophosphamide was beneficial for a short time and in similar cases a trial of cyclophosAcute systemic lupus erythematosus 69 phamide in higher doses and earlier in the illness may be indicated.
This patient represents the most severe end of the connective tissue disease spectrum. It is important to realise that despite the absence of renal disease and the presence of nRNP (previously associated with a good prognosis) severe and fatal problems such as acute lupus pneumonitis and DIC can occur. 
